Channel‑Selected Stratified Nested Cross‑Validation for Clinically Relevant EEG‑Based Parkinson’s Disease Detection
Nicholas R. Rasmussen, Rodrigue Rizk, Longwei Wang, Arun Singh, KC Santosh · 2026
Read Channel‑Selected Stratified Nested Cross‑Validation for Clinically Relevant EEG‑Based Parkinson’s Disease Detection by Nicholas R. Rasmussen, Rodrigue Rizk, Longwei Wang, Arun Singh, KC Santosh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2601-05276.txt.
Introduction
Nicholas R. Rasmussen and 4 co-authors set a strict test for tools that spot Parkinson's disease from brain-wave traces in a 2026 paper. Brain-wave reads are cheap, pain-free, and fit for mass checks of a crowd. Work with learned models had looked bright. But scores rest on a flaw: data from one sick soul leaked to both the train side and the test side of a run. That leak pumps scores up and blocks the road to the ward.
Their frame nests its checks so no such leak can slip in, and adds three guards. One makes sure no soul's data sits on both sides of a split. It also picks which wave paths to trust, in a nested way. What counts is not a top score on a slide, but a tool that holds up in a real ward, on souls it has not seen.
Catalog record
| CREATOR | Nicholas R. Rasmussen, Rodrigue Rizk, Longwei Wang, Arun Singh, KC Santosh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2601-05276
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Channel‑Selected Stratified Nested Cross‑Validation for Clinically Relevant EEG‑Based Parkinson’s Disease Detection Nicholas R. Rasmussen, Rodrigue Rizk, Longwei Wang, Arun Singh, KC Santosh Abstract The early detection of Parkinson’s disease remains a critical challenge in clinical neuroscience, with electroencephalography offering a non‑invasive and scalable pathway toward population‑level screening. While machine learning has shown promise in this domain, many reported results suffer from methodological flaws, most notably patient‑level data leakage, inflating performance estimates and limiting clinical translation. To address these modeling pitfalls, we propose a unified evaluation framework grounded in nested cross‑validation and incorporating three complementary safeguards: (i) patient‑level stratification to eliminate subject overlap and ensure unbiased generalization, (ii) multi‑layered windowing to harmonize heterogeneous EEG recordings while preserving temporal dynamics, and (iii) inner‑loop channel selection to enable principled feature reduction without information leakage. Applied across three independent datasets with a heterogeneous number of channels, a convolutional neural network trained under this framework achieved 80.6% accuracy and demonstrated state‑of‑the‑art performance under held‑out population block testing, comparable to other methods in the literature. This performance underscores the necessity of nested cross‑validation as a safeguard against bias and as a principled means of selecting the most relevant information for patient‑level decisions, providing a reproducible foundation that can extend to other biomedical signal analysis domains. I Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting over 10 million people worldwide and imposing a growing socioeconomic burden [ 1 ] . Its progressive course—marked by motor dysfunction, cognitive decline, and reduced quality of life—makes early detection and intervention a critical priority [ 2 , 3 ] . Yet current clinical diagnosis is largely based on overt motor symptoms, which typically emerge only after substantial dopaminergic neuron loss [ 2 , 3 ] . This delay highlights the importance of identifying prodromal biomarkers, such as REM sleep behavior disorder, olfactory impairment, and subtle motor irregularities, which often precede clinical diagnosis by years [ 2 ] . Detecting early PD could enable interventions when therapies are effective [ 2 ] . Advances in biomedical signal acquisition have created new opportunities for non‑invasive monitoring of these prodromal and progressive symptoms [ 4 ] . Among available modalities, electroencephalography (EEG) is particularly promising: it is portable, relatively inexpensive, and offers millisecond‑level temporal resolution of neural dynamics [ 5 ] . Compared to imaging techniques such as MRI or PET, which provide high spatial resolution but are costly and less accessible, EEG enables scalable, repeated assessments that are well‑suited for longitudinal monitoring [ 5 , 6 ] . This combination of accessibility and temporal precision positions EEG as a strong candidate for early PD biomarker discovery. Fig. 1: The nested cross‑validation architecture addresses the challenge of high‑dimensional EEG data by starting with all channels and systematically reducing to the most informative. The inner loop selects channels contributing most to inference, while the outer loop validates this choice without bias. This principled “many‑to‑best” reduction is dataset‑, channel‑, and model‑agnostic, yielding results that are more efficient, generalizable, and interpretable. In parallel, machine learning (ML) and deep learning (DL) methods show strong potential for extracting subtle biomarkers from high‑dimensional biomedical data [ 7 ] . A wide range of neural architectures have been explored for biosignal analysis: recurrent neural networks (RNNs) and long short‑term memory (LSTM) models capture temporal dependencies in sequential data [ 8 ] ; transformer‑based models leverage self‑attention to model long‑range interactions across time and frequency; and graph neural networks (GNNs) exploit the spatial topology of EEG electrode layouts to learn structured representations [ 9 ] . Despite these advances, convolutional neural networks (CNNs) remain a principled starting point for EEG analysis. When applied to short‑time Fourier transform (STFT) spectrograms, CNNs exploit partial shift‑invariance that complements the local stationarity of the STFT, enabling robust feature extraction without handcrafted preprocessing [ 10 , 11 , 12 ] . This synergy has consistently delivered state‑of‑the‑art performance across diverse signal domains, including PD detection, where CNN‑based or hybrid pipelines frequently report accuracies exceeding 95% [ 13 ] . Moreover, CNN architectures are naturally extensible to multimodal fusion: EEG inputs can be paired with bio-signal sensor data through parallel branches converging in shared layers, allowing integrated biomarker discovery without redesigning the core model [ 14 ] . Many reported successes in EEG‑based PD detection are undermined by methodological flaws, most notably data leakage and dataset heterogeneity. Leakage arises in two primary forms: temporal leakage , where overlapping windows from the same recording are split across training and test sets, and subject leakage , where data from the same patient appears in both folds. In both cases, models risk memorizing idiosyncratic traits rather than learning disease‑relevant features, inflating performance and eroding clinical validity [ 15 ] . Surveys of PD classification studies further highlight that EEG research often employs ambiguous patient‑level stratification, if it is applied at all [ 16 ] . Population block testing offers a partial safeguard, yet its scope is limited, as models may still overfit to the unique characteristics of a single cohort. These concerns are compounded by the heterogeneity of public EEG datasets: channel counts range from high‑density 64‑channel caps to sparse consumer devices, and acquisition hardware differs in sampling rate, electrode placement, and preprocessing pipelines. Methods tuned to one configuration often fail to transfer across others, creating a significant reproducibility barrier. Collectively, these challenges underscore the need for architectures that prevent leakage, generalize across populations, and robustly reduce high‑dimensional signals to the most informative subset, independent of dataset or recording setup. To address these challenges, we propose a nested cross-validation framework for robust EEG analysis (Figure 1 ). The outer loop enforces patient-level stratification to eliminate leakage, while the inner loop selects the most informative channels, reducing dimensionality without sacrificing clinically relevant signals. A multi-layered windowing strategy integrates recordings of varying length, sampling rate, and hardware, enabling consistent evaluation across heterogeneous datasets. By design, the framework is dataset, channel, and model-agnostic, positioning it as a blueprint for reproducible EEG-based biomarker discovery. Together, these components yield generalizable performance estimates and clinically meaningful early PD detection results. Our contributions are threefold: 1. A model‑agnostic nested cross‑validation framework with stratification, windowing, and inner‑loop channel selection to prevent leakage, harmonize datasets, and reduce dimensionality. 2. Empirical evidence that patient‑level leakage and narrow cohort blocking inflate EEG‑based PD detection performance and undermine clinical validity. 3. Demonstration that learned representations align with canonical EEG frequency bands, yielding interpretable models that achieve 0.806 accuracy across datasets. Looking forward, this framework provides a foundation for accelerating clinical translation: it enables reproducible biomarker validation across heterogeneous cohorts, supports integration with multimodal data streams such as EMG and wearable sensors, and lays the groundwork for scalable digital health pipelines capable of monitoring neurodegenerative disease progression in real-world settings. II Related Work and Methodological Pitfalls A growing body of research has applied ML techniques to the early detection of PD using EEG, EMG, and other biosignal modalities. Several studies have reported high classification accuracies, often exceeding 85%, suggesting strong potential for clinical translation [ 17 , 18 ] . However, closer inspection reveals that many of these works rely on evaluation protocols that do not stratify data at the patient level. Instead, temporal windows from the same subject are